How Much New Eli Lilly Product Launches Boosted the Bottom Line
Eli Lilly reported better-than-expected second-quarter earnings Thursday before the markets opened.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Eli Lilly and Co. (NYSE: LLY) reported its second-quarter earnings Thursday before the markets opened. The company had $0.90 in earnings per share (EPS) on $4.98 billion in revenue. That was against Thomson Reuters consensus estimates of $0.74 in EPS on $4.91 billion in revenue. In the same period of the previous year EPS were $0.68 and revenue $4.94 billion.
Guidance for the 2015 full year EPS was revised to $3.20 to $3.30, reflecting solid underlying performance in the first six months of the year. Revenue guidance was revised to $19.7 billion to $20.0 billion, up from $19.5 billion to $20.0 billion. The consensus estimates are $3.18 in EPS on $19.80 billion in revenue for the 2015 full year.
For the most recent quarter, gross margin as a percentage of revenue was 79.2%, an increase of 250 basis points from the second quarter of 2014. The increase in gross margin percentage was due to the impact of foreign exchange rates on international inventories sold.
In terms of its product sales, Eli Lilly reported (on a year-over-year basis):
- Humalog, $654.3 million, down 7%
- Alimta, $664.3 million, down 7%
- Cialis, $567.9 million
- Humlin, $316.4 million, down 10%
- Forteo, $328.4 million, up 6%
- Cymbalta, $274.1 million, down 32%
- Zyprexa, $253.7 million, up 4%
- Strattera, $191.8 million, down 3%
- Effient, $128.8 million, down 4%
- Trajenta, $80.0 million, down 11%
- Cyramza, $87.7 million
- Evista, $59.7 million, down 45%
- Animal Health, $840.8 million, up 40%
ALSO READ: 5 S&P 500 Companies That Are Buying Back the Most Stock
John C. Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly, said:
Lilly remains on track to return to growth in 2015, driven by strong underlying business performance, including uptake of our recently launched products — Jardiance, Trulicity and Cyramza. With tangible results from launches of new medicines and continued progress in our pipeline, along with careful control of operational expenses, we are confident that our innovation-based strategy will continue to provide the basis for solid growth in the years ahead.
Shares of Eli Lilly were flat at $86.41 Thursday morning. The stock has a consensus analyst price target of $89.71 and a 52-week trading range of $60.14 to $90.18.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
